Aarti Drugs Ltd

- The transcript does not mention any immediate or future plans for fundraising through debt or equity. - Current total consolidated debt is around INR 540 crores, split roughly equally between long-term and short-term. - The company emphasizes strict capital discipline while executing growth projects. - Capex of INR 150-200 crores per year for the next 2 years is planned, funded presumably through internal accruals and existing debt capacity. - No specific discussions or announcements regarding new debt or equity fundraising were made during the call.

- INR 150-200 crores annual capex expected for next 2 years, covering new projects and maintenance. - Investments include oncology dossier development, formulation expansion, and brownfield expansions. - Greenfield projects nearing completion; ramp-up expected within 6-24 months for Sayakha and salicylic acid plants. - Plans to expand metformin facility to 2,500-3,000 tons/month (currently 1,450-1,500 tons), including US FDA approvals and potential ANDA launch via Pinnacle. - Capacity expansion for cardiovascular and antifungal products. - Exploring CDMO opportunities in chlorosulfonation chemistry and methylamine derivatives. - Strategic focus on backward integration, increasing operational efficiency, and entry into regulated and semi-regulated markets. - Capex also includes energy improvements like large cogen boiler at Baddi.

- FY '26 growth was below expectations; volume growth of 15% in H2 is pushed into FY '27. - Expected volume growth of 12% to 15% in FY '27 driven mainly by new projects (salicylic acid and Sayakha amines). - Existing product basket projected to deliver single-digit volume growth. - Formulations, especially oncology and exports, expected to grow, with formulations playing a larger role in future revenue. - Ramp-up of Sayakha plant utilization expected from 30% to 50% by March/April 2026, reaching 75% thereafter, supporting volume growth. - Stabilizing realizations and improving demand trend from January 2026 indicate a positive sales momentum going forward. - Expanding regulated market sales (Europe, U.S.) with approvals expected to enhance revenue and improve gross margins.

- Aarti Drugs anticipates a new growth phase as strategic investments begin aligning, with more significant financial impact expected in upcoming quarters due to increased capacity utilization and improved product mix. - Volume growth of 12-15% is expected in FY '27, driven mainly by new projects like salicylic acid and Sayakha methylamines. - EBITDA margins target to recover to 12-13% initially, then stabilize around 14-15% as operations normalize. - Gross margin for standalone API business is expected around 36%, supported by regulated market sales and backward integration benefits. - Capex of INR150-200 crores annually for next 2 years includes oncology dossiers and expansions aiming to enhance long-term profitability. - PAT showed strong YoY growth (+58% for Q3 FY26), with operational efficiencies and exports expected to further improve profits. - New product approvals and European certifications will boost formulations and regulated market revenue, improving EPS over time.

The transcript provided does not explicitly mention the current or expected order book or pending orders for Aarti Drugs Limited. There is no direct disclosure regarding order backlog or pending orders in the Q3 & 9M FY26 Earnings Conference Call transcript excerpt shared on page 15 or surrounding pages. Key points relevant to demand outlook and capacity utilization include: - The company saw 7% volume growth in the standalone business segment year-on-year. - The Sayakha facility ramp-up is progressing well, targeting 50% utilization by March-April 2026 and higher subsequently, indicating incoming demand. - Export markets, especially formulations, are a key growth driver. - January sales trends are encouraging, suggesting improving demand. - The company anticipates 12-15% volume growth in FY27 with new project ramp-ups. However, exact figures or status of order book/pending orders are not disclosed in this transcript.